Healthcare101

 The global biopharmaceutical contract manufacturing market , valued at US$20.51 billion in 2024 , stood at US$22.40 billion in 2025 and is projected to grow at a CAGR of 8.8% from 2025 to 2030, reaching a forecasted US$34.15 billion by 2030 . This robust growth reflects the rising global demand for outsourcing services, fueled by increasing biologics and biosimilars production, as well as the expanding prevalence of chronic and rare diseases. However, the market faces certain barriers related to intellectual property (IP) rights and compliance with stringent regulatory frameworks. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163964739 Attractive Opportunities in the Biopharmaceutical Contract Manufacturing Market The biopharmaceutical contract manufacturing market presents strong opportunities across multiple regions, with Asia Pacific emerging as a particularly attractive hub. The growth of the Asia Pacific market is driven by: ...

 In modern medicine, diagnostics are rapidly moving toward less invasive, more precise, and real-time approaches . One of the most transformative innovations driving this change is liquid biopsy —a technique that is reshaping how diseases, especially cancer, are detected and monitored. The liquid biopsy market is estimated at USD 4.03 billion in 2025 and is projected to reach USD 7.05 billion by 2030, growing at a CAGR of 11.8% during the forecast period.  📌 What Is a Liquid Biopsy? A liquid biopsy is a diagnostic test that analyzes biological markers found in body fluids—most commonly blood—to gather information about a disease. 👉 In simple terms: Instead of surgically removing tissue, doctors can “read” disease signals from a blood sample. These signals may include: Circulating tumor DNA ( ctDNA ) Circulating tumor cells ( CTCs ) Cell-free DNA ( cfDNA ) RNA, proteins, or exosomes Download PDF Brochure: https://www.marketsa...